Accessibility Menu

Radiopharm Theranostics

(NASDAQ) RADX

Current Price$4.11
Market Cap$51.16M
Since IPO (2024)-76%
5 YearN/A
1 Year-7%
1 Month-6%

Radiopharm Theranostics Financials at a Glance

Market Cap

$51.16M

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

-$2.94

P/E Ratio

-1.47

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$4.11

Volume

60,539

Open

$4.27

Previous Close

$4.02

Daily Range

$3.95 - $4.27

52-Week Range

$3.62 - $16.25

Estimated Earnings Date

Sep 24, 2026

RADX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Radiopharm Theranostics

Industry

Biotechnology

Sector

Health Care

CEO

Riccardo Canevari

Website

radiopharmtheranostics.com

Headquarters

Carlton, VIC 3053, AU

RADX Financials

Key Financial Metrics (TTM)

Gross Margin

172.70%

Operating Margin

-402.78%

Net Income Margin

-363.95%

Return on Equity

-93.08%

Return on Capital

-85.22%

Return on Assets

-49.29%

Earnings Yield

-68.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$51.16M

Shares Outstanding

11.81M

Volume

60.54K

Avg. Volume

36.60K

Financials (TTM)

Gross Profit

A$39.28K

Operating Income

-A$38.17M

EBITDA

-A$38.17M

Operating Cash Flow

-A$33.46M

Capital Expenditure

A$0.00

Free Cash Flow

-A$33.46M

Cash & ST Invst.

A$36.44M

Total Debt

A$0.00

Radiopharm Theranostics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$51.16M

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics, Inc.
$3.38+6.62%
BCLIBrainstorm Cell Therapeutics Inc.
$0.93-1.06%
QNRXQuoin Pharmaceuticals, Ltd.
$4.45+5.95%
TCRTAlaunos Therapeutics, Inc.
$2.08+0.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.87+0.02%
SPCXSpace Exploration Technologies
$153.23+0.00%
ONDSOndas
$7.83+0.02%
HLHecla Mining
$15.54+0.03%

Questions About RADX

What is the current price of Radiopharm Theranostics?

Radiopharm Theranostics is trading at $4.02 per share.

What is the 52-week range for Radiopharm Theranostics?

Over the past 52 weeks, Radiopharm Theranostics has traded between $3.62 and $16.25.

How much debt does Radiopharm Theranostics have?

As of the most recent reporting period, Radiopharm Theranostics reported total debt of A$0.00.

How much cash does Radiopharm Theranostics have on hand?

Radiopharm Theranostics reported A$19.08M in cash and cash equivalents in its most recent financial results.

What is Radiopharm Theranostics’s dividend yield?

Radiopharm Theranostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services